Want to see SE:CANTA full AI Analyst Report?
CANTA Stock Chart & Stats
kr4.07
-kr0.02(-1.25%)
At close: 4:00 PM EST
kr4.07
-kr0.02(-1.25%)
Day’s Range― - ―
52-Week Rangekr1.13 - kr6.59
Previous CloseN/A
Volume611.88K
Average Volume (3M)1.42M
Market Cap
kr539.49M
Enterprise Valuekr288.48M
Total Cash (Recent Filing)kr258.03M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)3.3
Beta0.84
Next Earnings
Aug 19, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding248,611,650
10 Day Avg. Volume1,074,033
30 Day Avg. Volume1,417,172
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.91
Price to Sales (P/S)3.28
P/FCF Ratio6.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr14.00Price Target Upside243.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowCantargia's TTM operating cash flow (158.1m) and free cash flow (157.6m) demonstrate the company produced meaningful internal cash in the latest period. Strong FCF supports ongoing clinical R&D and reduces near-term reliance on dilution, providing runway and optionality for partnerships or selective investment.
Zero Debt Balance SheetA zero-debt capital structure materially lowers solvency and interest-rate risk for a clinical-stage biotech. This enhances strategic flexibility during long development timelines, allowing Cantargia to prioritize R&D or collaboration terms over servicing debt, and preserves capacity to raise capital on favorable terms if needed.
High TTM ProfitabilityThe TTM step-up to 317.2m revenue with ~51% net/EBIT margin indicates the company can realize high-margin inflows, likely from licensing or milestone events. If Cantargia converts such events into repeatable partnership revenues or commercial sales, this margin profile can sustain cash generation and fund scale-up of clinical programs.
Bears Say
Episodic RevenueHistorical volatility—multi-year zero revenue followed by a TTM spike—suggests revenues may be driven by one-off milestones or licensing rather than recurring product sales. This episodic pattern makes cash flow forecasting and R&D planning uncertain and increases the chance of future funding needs if milestone timing is uneven.
Declining Equity / Dilution RiskA decline in shareholder equity relative to the prior year and below earlier peaks reflects prior losses and likely capital raises. For a biotech without marketed products, this pattern signals potential future dilution to finance trials, which can constrain long-term shareholder value and limit financial flexibility absent steady revenue.
Funding Model DependencyThe company's primary reliance on equity raises, partner upfronts and milestone/licensing payments rather than product revenue creates structural funding volatility. Long-term program continuity depends on access to capital markets or partner deals, exposing operations to market cycles and negotiation outcomes.
Cantargia AB News
CANTA FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was kr1.13 and its highest was kr6.59 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is kr539.49M.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is Aug 19, 2026 which is in 47 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on May 19, 2026. The company reported -kr0.13 earnings per share for the quarter, beating the consensus estimate of -kr0.18 by kr0.05.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Undervalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate is -0.17.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 248,611,650 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of -kr0.13 in its last earnings report, beating expectations of -kr0.18. Following the earnings report the stock price went down -1.18%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in SE:CANTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cantargia AB
Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.
CANTA Stock 12 Month Forecast
Average Price Target
kr14.00
▲(243.98% Upside)
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
―
Guard Therapeutics International AB
―
Immunicum AB
―
Options Prices
Currently, No data available
---